EPIX צמיחת רווחי EPS רבעונית ESSA Pharma
ESSA Pharma Inc. (EPIX) develops targeted oncology drugs, where success depends on FDA approval and patents. The quarterly earnings per share growth rate reflects the business revaluation dynamics, and this figure equals 43.90. Management is focusing on innovative receptor blocking for the therapy of resistant forms of cancer. The Aniten platform provides a stable moat, enabling the suppression of dangerous tumors in collaboration with industry leaders.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_EPIX_-_ESSA-Pharma-Inc._-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "ESSA Pharma, Inc. (EPIX): צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים מ-04.07.2022 עד 25.10.2025 | 👁️GURU.Markets👁️")
פילוחי נתונים אנליטיים מרוכזים עבור ESSA Pharma Inc. (EPIX)
ESSA Pharma Inc. is developing innovative targeted prostate cancer therapies, where brand capitalization depends on the success of clinical developments. By analyzing the quarterly EPS growth vector on GURU.Markets, an investor can track net profit per share compared to previous periods, allowing for an assessment of technology commercialization efficiency and the sustainability of the company's fundamental trend.
